Utilizes next-generation sequencing for high-sensitivity detection of genetic variants in cancer samples.
Includes panels for somatic and germline mutations, covering key cancer-related genes and pathways.
Non-invasive testing via blood samples to monitor tumor dynamics and treatment response over time.
Integrates bioinformatics and clinical databases to provide evidence-based therapeutic recommendations.
Adheres to CLIA, CAP, and other regulatory standards for diagnostic testing.
Delivers results within 10-14 business days from sample receipt.
Provides access to genetic counselors and scientific liaisons for result interpretation and consultation.
Identify specific genetic mutations in tumors to accurately diagnose cancer types and subtypes, guiding initial treatment strategies.
Use genomic profiles to match patients with FDA-approved targeted drugs, such as EGFR inhibitors for lung cancer.
Assess biomarkers like tumor mutational burden (TMB) or MSI status to predict efficacy of immunotherapies like checkpoint inhibitors.
Track changes in circulating tumor DNA via liquid biopsy to evaluate treatment effectiveness and detect early signs of resistance.
Detect low-level residual cancer cells after surgery or therapy to assess recurrence risk and guide adjuvant treatments.
Identify eligible patients for precision oncology trials based on specific genetic alterations, accelerating recruitment.
Screen for germline mutations in genes like BRCA1/2 to assess inherited cancer risk and inform preventive measures.
Correlate genomic signatures with clinical outcomes to predict disease progression and survival rates.
Provide genomic data for pharmaceutical companies to identify biomarkers and develop new targeted therapies.
Create customized follow-up schedules based on genomic risk profiles, optimizing long-term patient management.
Sign in to leave a review
Guardant Health is a precision oncology company that specializes in liquid biopsy tests for cancer detection and monitoring. Their advanced tests, such as Guardant360 and Guardant Reveal, analyze circulating tumor DNA from a blood sample to provide comprehensive genomic profiling. This non-invasive approach allows for early cancer detection, treatment selection, and monitoring of therapy response. By leveraging next-generation sequencing and artificial intelligence, Guardant Health delivers accurate and timely results, typically within 7-14 days. The tests are designed to overcome the limitations of traditional tissue biopsies, offering a safer and more convenient alternative. Used by oncologists worldwide, Guardant Health's solutions empower personalized cancer care, improve patient outcomes, and support clinical research. With a focus on innovation, the company continues to develop new assays to address various cancer types and stages, enhancing global healthcare through cutting-edge technology and evidence-based practices.
